NasdaqGS:ZBIOBiotechs
How Positive MoonStone Data and New Deals Could Shape Zenas BioPharma’s (ZBIO) Immunology Ambitions
Zenas BioPharma announced in November 2025 that it reported highly positive Phase 2 results for obexelimab in relapsing multiple sclerosis, secured a US$300 million funding agreement with Royalty Pharma, and entered a licensing deal with InnoCare Pharma for orelabrutinib and early-stage assets.
These clinical and business milestones provided both scientific validation and financial support for Zenas BioPharma's expanding focus in autoimmune disease treatments.
We'll explore how the...